Biogen Idec (NQ:BIIB)

219.88 -2.94 (-1.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

62 63 Next >

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗

May 14, 2025

Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.

Via Benzinga

Topics Stocks

3 Cash-Producing Stocks Skating on Thin Ice

May 13, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

14 Analysts Have This To Say About Biogen ↗

April 22, 2025

Via Benzinga

How Is The Market Feeling About Biogen? ↗

March 07, 2025

Via Benzinga

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore

May 06, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

4 Stocks to Buy for a Potential “Summer Panic” ↗

May 04, 2025

Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create...

Via InvestorPlace

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact ↗

May 01, 2025

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Via Benzinga

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets

May 01, 2025

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was...

Via StockStory

Topics Artificial Intelligence

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Biogen Earnings: What To Look For From BIIB

April 30, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

April 24, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion ↗

April 16, 2025

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.

Via Benzinga

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

April 15, 2025

From Biogen Inc.

Via GlobeNewswire

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. ↗

April 10, 2025

From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.

Via Investor's Business Daily

Topics Government

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

What 14 Analyst Ratings Have To Say About Biogen ↗

April 04, 2025

Via Benzinga

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

April 02, 2025

From Biogen Inc.

Via GlobeNewswire

European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen ↗

March 28, 2025

Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.

Via Benzinga

Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 ↗

March 27, 2025

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.

Via The Motley Fool

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

March 24, 2025

From Biogen Inc.

Via GlobeNewswire

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

March 11, 2025

From Biogen Inc.

Via GlobeNewswire

Indexes Swimming In Red Ink On Recession Fears ↗

March 10, 2025

Stocks are looking to extend last week's losses, as recession fears grip Wall Street.

Via Talk Markets

Topics Economy Stocks / Equities

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.